ICH E6 (R3): Guide to Implementation

Get ready to work with the new GCP ICH E6 R3 guideline

Date icon

4 Mar 2025

Attendance icon

On location

Language icon

English

Price icon
7,000 DKK ex VAT

(app. 941 EUR ex VAT)

50% DISCOUNT FOR PUBLIC INSTITUTIONS

Summary


The new ICH E6 R3 guideline represents a significant change in clinical trial management.

When implementing this new guideline, you need to reconsider your current processes.

While ICH E6 R3 may present challenges, it's a guideline that the industry should strongly consider adopting in due course. The potential benefits of implementation are likely to outweigh the costs associated with change. It introduces updates that aim to make the guidelines more flexible and adaptable, encouraging a risk-based approach.

We have organized a comprehensive day of learning, where you will gain insights into what it takes to comply with the new guidelines.

Among other topics, you will learn to implement a risk-based approach, which will make your clinical trials more effective and less resource-intensive.

The course will feature a panel of lecturers representing regulatory authorities and the pharmaceutical industry. This format allows for constructive discussions and valuable outcomes.

The day will include workshop sessions, with the intention of making the experience as interactive as possible.


Keywords

  • ICH-GCP
  • Quality by design
  • Risk management
  • Data governance
  • Feasibility

Save information for later
Read more

Course leader & lecturers

  • Lisbeth Bregnhøj
    Course leader
    GCP Inspector
    Danish Health and Medicines Authority
  • Susanne Nørskov
    Course leader
    VP Global Clinical Compliance
    Novo Nordisk A/S
  • William Andy Lawton
    Course leader
    Consultant/Director
    Risk Based Approach Ltd
See all

Is this course for you?

The course is designed for both sponsor and site employees. This is because compliance is a shared responsibility, and it's beneficial for both parties to understand the impact of the guidelines, enabling more effective communication.

What you will learn

  1. Background to the changes and ICH objectives for ICH GCP
  2. ICH E6 R3 – Investigator and Site staff impact
  3. ICH E6 R3 – Sponsor/Vendor impact
  4. Changes for Investigator, Site staff and sponsor
  5. Regulatory and Pharma perspectives

What your company will get

  1. An employee who is familiar with the background to the changes and ICH objectives for ICH GCP
  2. An employee who knows which impact ICH E6 R3 has on investigator and sponsor, and what is needed to implement the changes
  3. An employee who knows which impact ICH E6 R3 has on Sponsor/Vendor and what is needed to implement the changes
  4. An employee who knows the perspective from the regulatory authorities and the pharma industry, and is, therefore, well-prepared to implement R3

Course calendar

4 Mar 2025 9:00-16:00
Day 1
  • ICH E6 R3 – Investigator and Site staff impact
  • ICH E6 R3 – Sponsor/Vendor impact
  • Investigator and Site staff changes
  • Sponsor changes
  • Regulatory perspective
  • Pharma perspectives
      Practical information

      Registration

      Registration deadline
      25 Feb 2025
      Atrium
      Lersø Parkallé 101
      2100 København Ø
      Register
      4 Mar
      Sometimes things change. This is the expected programme.

      Course information

      Prerequisites

      Previous knowledge of ICH E6 R2.

      Examination

      There is no examination for this course.

      Course leaders

      Lisbeth Bregnhøj
      GCP Inspector
      Danish Health and Medicines Authority
      Susanne Nørskov
      VP Global Clinical Compliance
      Novo Nordisk A/S
      William Andy Lawton
      Consultant/Director
      Risk Based Approach Ltd

      You may also be interested in these courses

      Want to know more or need help?

      Contact Client Manager Christina Spangsberg at +45 39 15 09 22

      Send me a message